Research Article

Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients

Volume: 19 Number: 4 October 10, 2026
EN TR

Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients

Abstract

Purpose: Long non-coding RNAs and microRNAs are considerable regulators of breast-cancer development, their clinicopathological relevance highly studying. We explored the association between NEAT1 and miR-211 expression levels and key clinicopathological features in a Turkish cohort of patients with breast cancer.
Materials and methods: Serum from treatment-naïve 59 breast cancer patients, and healthy 45 age-matched controls were analyzed. Total RNA was extracted, reverse-transcribed, and quantified by qRT-PCR and target gene analysis was performed. Studied clinicopathological variables included estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67 index, p53 status, size of tumor, body mass index, lymph-node metastasis, and pathological stage.
Results: Substantial positive relation was discovered between Ki67 and P53 expression levels indicating that increased proliferative activity may be associated with higher P53 expression in tumor samples. This finding supports the possibility of a coordinated role of these markers in tumor progression, suggesting its association with proliferative characteristics. Although miR-211 did not exhibit significant clinicopathological correlations, its downregulation was more pronounced in patients who developed metastases. A strong concordance was observed between ER and PR status, and Ki-67 expression was significantly lower in ER- and PR-positive tumors. Additionally, the stage was positively associated with tumor size and nodal status.
Conclusions: NEAT1 over-expression accompanies higher proliferation and greater tumor burden in primary breast cancer, supporting its candidacy as a prognostic biomarker or therapeutic target. In the axis, miR-211 is thought to be downregulated by NEAT1 in breast carcinogenesis.

Keywords

Supporting Institution

Scientific Research Coordination Unit of Pamukkale University

Project Number

2020SABE01

Ethical Statement

Permission was obtained from Pamukkale University Non-Interventional Clinical Research Ethics Committee for the study. (permission number: 60116787-020/10335 permission date: 05.02.2020)

Thanks

no

References

  1. Jiang WW, Wang YM, Wang XY, Zhang Q, Zhu SM, Zhang CL. Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models. Chin Med J (Engl). 2019;132(17):2079-2088. doi:10.1097/CM9.0000000000000412
  2. Baroni A, Buommino E, De Gregorio V, Ruocco E, Ruocco V, Wolf R. Structure and function of the epidermis related to barrier properties. Clin Dermatol. 2012;30(3):257-262. doi:10.1016/j.clindermatol.2011.08.007
  3. Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526. doi:10.3390/IJMS18122526
  4. Zhou Q, Yu Q, Gong Y. Construction of a lncRNAmiRNAmRNA network to determine the regulatory roles of lncRNAs in psoriasis. doi:10.3892/etm.2019.8035
  5. Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:75-82. doi:10.2147/PTT.S146004
  6. Catia de Felice C, Marulli GC, Ardigò M, Berardesca E. Biological markers in the etiology of psoriasis: Targeted treatment options. 2007;1(1):11-18.
  7. Jia HY, Zhang K, Lu WJ, Xu GW, Zhang JF, Tang ZL. LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR-21/caspase-8. BMC Mol Cell Biol. 2019;20(1):1-13. doi:10.1186/S12860-019-0229-9/TABLES/1
  8. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;48(3):R45-R53. doi:10.1530/JME-12-0008

Details

Primary Language

English

Subjects

General Surgery

Journal Section

Research Article

Publication Date

October 10, 2026

Submission Date

January 2, 2026

Acceptance Date

February 27, 2026

Published in Issue

Year 2026 Volume: 19 Number: 4

APA
Yilmaz, S., Acikbas, I., Er Urganci, A. B., Simsek, S., Azizi, Z., & Dogan, C. (2026). Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients. Pamukkale Medical Journal, 19(4), 685-696. https://doi.org/10.31362/patd.1854750
AMA
1.Yilmaz S, Acikbas I, Er Urganci AB, Simsek S, Azizi Z, Dogan C. Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients. Pam Med J. 2026;19(4):685-696. doi:10.31362/patd.1854750
Chicago
Yilmaz, Sevda, Ibrahim Acikbas, Aysen Buket Er Urganci, Selda Simsek, Zahra Azizi, and Cihangir Dogan. 2026. “Role of NEAT1 MiR-211-3p Axis in the Serum of Breast Cancer Patients”. Pamukkale Medical Journal 19 (4): 685-96. https://doi.org/10.31362/patd.1854750.
EndNote
Yilmaz S, Acikbas I, Er Urganci AB, Simsek S, Azizi Z, Dogan C (October 1, 2026) Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients. Pamukkale Medical Journal 19 4 685–696.
IEEE
[1]S. Yilmaz, I. Acikbas, A. B. Er Urganci, S. Simsek, Z. Azizi, and C. Dogan, “Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients”, Pam Med J, vol. 19, no. 4, pp. 685–696, Oct. 2026, doi: 10.31362/patd.1854750.
ISNAD
Yilmaz, Sevda - Acikbas, Ibrahim - Er Urganci, Aysen Buket - Simsek, Selda - Azizi, Zahra - Dogan, Cihangir. “Role of NEAT1 MiR-211-3p Axis in the Serum of Breast Cancer Patients”. Pamukkale Medical Journal 19/4 (October 1, 2026): 685-696. https://doi.org/10.31362/patd.1854750.
JAMA
1.Yilmaz S, Acikbas I, Er Urganci AB, Simsek S, Azizi Z, Dogan C. Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients. Pam Med J. 2026;19:685–696.
MLA
Yilmaz, Sevda, et al. “Role of NEAT1 MiR-211-3p Axis in the Serum of Breast Cancer Patients”. Pamukkale Medical Journal, vol. 19, no. 4, Oct. 2026, pp. 685-96, doi:10.31362/patd.1854750.
Vancouver
1.Sevda Yilmaz, Ibrahim Acikbas, Aysen Buket Er Urganci, Selda Simsek, Zahra Azizi, Cihangir Dogan. Role of NEAT1/miR-211-3p axis in the serum of breast cancer patients. Pam Med J. 2026 Oct. 1;19(4):685-96. doi:10.31362/patd.1854750

Creative Commons Lisansı

Pamukkale Medical Journal is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC).